MICROT PR Center
We are a medical device company dedicated to
treating glaucoma, the second leading cause of blindness worldwide.
By providing safe and reliable treatment alternatives, we aim to true innovation that delivers real value to both healthcare professionals and patients in clinical settings.
We pursue improve the quality of life for glaucoma patients around the world through better access to care.
- OUR VISION
- OUR HISTORY
OUR VISION
INNOVATIVE TECHNOLOGY
SAFE AND EASY
TOTAL MEDICAL SERVICE
REASONABLE PRICE POLICY
OUR HISTORY
2025
- Secured Code-in at Korea's Top 5 Teritory General Hospitals
- A-stream Glaucoma Shunt Surpassed 1,500 Surgical Cases
- Completed Series B Funding Round
- Selected as a Promising Tech Company for Global Investment by Gyeonggi Province
- A-stream Glaucoma Shunt Approved for Reimbursement under Korean National Health Insurance
- Completed Series A-Bridge Funding Round
- Certified as an Excellent Employment Enterprise by Seongnam City
- Selected for a Program by the Ministry of SMEs and Startups
- Selected as a Promising Small Enterprise by the Ministry of Employment and Labor
- Selected as a “Baby Unicorn” Company by the Ministry of SMEs and Startups
- Awarded for Excellence in Employee Invention Compensation by the Korean Intellectual Property Office
- A-stream Glaucoma Shunt Korean MFDS (Ministry of Food and Drug Safety) approval
- Selected for the Baby Unicorn 200 Cultivation project
- Completed Series A Funding Round
- Selected as a Frontier Venture Company
- Selected as a TECH Valley Enterprise
- Completed development of the glaucoma implant
- Registered as a Medical Device Sales Business
- Acquired license for Medical Device Manufacturing
- Established MICROT Co., Ltd.
- Started development of medical-grade prototypes
- Accredited as a Corporate R&D Center
- Formed joint research collaborations for core technology development with KAIST, Sungkyunkwan University, and Chungbuk National University
- Collected data and clinical evidence for glaucoma implant
- Filed and obtained patents related to glaucoma implants and began product commercialization
- Selected for the Pre-Startup Program